Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TRANS-INT

Financiado

Cerrado

New Oral Nanomedicines Transporting Therapeutic Macromolecules across the Intes...

New Oral Nanomedicines Transporting Therapeutic Macromolecules across the Intestinal Barrier Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashi... ver más

30/04/2017

USC

11M€

Presupuesto del proyecto: 11M€

Líder del proyecto

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 238

Fecha límite participación Sin fecha límite de participación.

Ver 19 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-04-30 No tenemos la información de la convocatoria

0% 74% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

19 Participantes

USC

0.00€ | Lider

UCC

N.D. | Participante

FUNDACIO INSTITUT DE RECERCA...

N.D. | Participante

I.O.V.

N.D. | Participante

Proyectos interesantes

SAF2016-79230-R

Medical Technol...

Nanotechnology

97K€ Cerrado

PathChooser

Nanotechnology

Medical Technol...

3M€ Cerrado

RTI2018-099227-B-I00

Medical Technol...

Nanotechnology

182K€ Cerrado

NeuroMOF

Medical Technol...

Nanotechnology

161K€ Cerrado

HsrELPnano

Medical Technol...

Nanotechnology

188K€ Cerrado

EndoNaut

Nanotechnology

Medical Technol...

150K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA No se ha especificado una descripción o un objeto social para esta compañía.

Total investigadores 238

Presupuesto del proyecto 11M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improvement of classical therapies and it would also make a high number of new therapies feasible. To make this happen, the final objective of Trans-INT is to design nanocarriers specifically adapted to deal with the gastrointestinal ecosystem and use them for the development of new oral nanomedicines for diseases with high socioeconomic impact (i.e. metabolic diseases, pain medication). The concept behind TRANS-INT is the rational design of oral nanomedicines based on safety, mechanistic, bioengineering (multifunctional nanocarriers: high payload, drug protection, efficient drug transport, controlled release) and pharmaceutical technology criteria (scalable technology and stability). The project will start with nanocarrier platforms on which the partners have IPR and freedom to operate: nanocapsules, nanoparticles, micelles made of combinations of lipids, polypeptides and polysaccharides, continue with the optimization and redefinition of selected nanocarriers. It is expected to end with (i) at least one oral nanocarrier prototype with a comprehensive GLP-tox package, which could be applied for the delivery of a high number of peptide molecules, (ii) at least one nanomedicine fulfilling target product profile criteria, with a comprehensive preclinical evaluation package, (iii) substantial integrative knowledge on the feasibility and potential of oral nanocarriers and nanopharmaceuticals. TRANS-INT is expected to have a great impact no only from the new therapies/patients perspective but also from the innovation and EU industrial development perspective.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores